Biostar Pharmaceuticals, Inc.

BSPM

US0906783016

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:42:37 2024-04-23 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI
2023	Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	CI

Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director

December 18, 2017 at 04:30 pm EST

Biostar Pharmaceuticals, Inc. announced resignation of Leung King Fai as an independent director of the Board of Directors, effective as of December 12, 2017. At the time of his resignation, he served as the Chairman of the Audit Committee of the Board.

Latest news about Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	23-06-15	CI
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	23-06-12	CI
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.	19-06-01	CI
Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index	18-09-18	CI
Waiping Liu Discloses its Plans on Biostar Pharmaceuticals	18-07-02	CI
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.	18-07-01	CI
Biostar Pharmaceuticals, Inc. Announces Board Changes	18-02-02	CI
Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee	17-12-28	CI
Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director	17-12-18	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-20	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-11-15	CI
Biostar Pharmaceuticals Seeks Acquisitions	17-11-15	CI
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd.	17-09-06	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-19	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016	17-04-13	CI
Biostar Pharmaceuticals, Inc. Announces Management Changes	17-02-09	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-21	CI
Biostar Pharmaceuticals, Inc. to Launch New Product Aimed at Treating Effects of Rhinitis and Sinusitis	16-10-11	CI
Biostar Pharmaceuticals, Inc. executed a non-binding letter of intent to acquire Xianyang Yongsheng Health Products Co., Ltd.	16-09-21	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-08-22	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016	16-05-23	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2015	16-04-14	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2015	15-11-23	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results of the Second Quarter and Six Months Ended June 30, 2015	15-08-19	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	15-05-15	CI

Chart Biostar Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People's Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company's products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company's products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOSTAR PHARMACEUTICALS, INC.	-.--%	263
ELI LILLY AND COMPANY	+33.25%	699B
NOVO NORDISK A/S	+28.59%	571B
JOHNSON & JOHNSON	-3.55%	364B
MERCK & CO., INC.	+18.16%	326B
ABBVIE INC.	+4.36%	286B
ASTRAZENECA PLC	+14.81%	236B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	149B

Other Pharmaceuticals